Half-year report · Q2
2784.TEDINET S100UPC8
Period2024-04-01 → 2024-09-30
Filed2024-11-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.46T | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥2.86T | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.43T | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥15.0bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥16.0bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥16.3bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥40.0bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥17.3bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥20.7bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥17.4bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥14.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥29.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥11.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥13.8bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥11.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥1.47T | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥1.45T | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥1.43T | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥975.8bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥967.8bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥491.3bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥479.9bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥465.6bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥206.8bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥213.8bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥204.6bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥212.3bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥184.8bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥158.8bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥2.9bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥86.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥63.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥8.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥14.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥8.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥7.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥19.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥29.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥75.26 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥154.13 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥60.29 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 33.5% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.1% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.6% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥18.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥18.0bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | ¥174m |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.30T |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.29T |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥9.6bn |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥12.7bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥27.0bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥18.9bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥8.1bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥188m |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥18.4bn |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥18.4bn |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥248m |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥132.4bn |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥132.1bn |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥258m |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥1.47T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥1.46T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥18.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥14.8bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥16.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥16.9bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | ¥269m |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.27T |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.26T |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥8.9bn |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥13.8bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥26.0bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥18.3bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥7.7bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥186m |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥18.2bn |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥18.2bn |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥279m |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥133.3bn |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥133.1bn |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥275m |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥1.44T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥1.43T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥16.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥15.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 562
| Item | Context | Value | Unit |
|---|---|---|---|
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |